IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 10.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,466 shares of the medical research company's stock after purchasing an additional 1,916 shares during the period. Rafferty Asset Management LLC's holdings in IQVIA were worth $4,022,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the company. Norges Bank bought a new stake in IQVIA in the 4th quarter valued at $336,041,000. Raymond James Financial Inc. acquired a new position in IQVIA during the 4th quarter valued at about $236,120,000. American Century Companies Inc. lifted its position in IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after purchasing an additional 905,960 shares during the period. Invesco Ltd. increased its stake in shares of IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after acquiring an additional 902,226 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in shares of IQVIA by 20.0% in the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after acquiring an additional 712,958 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on IQV shares. JPMorgan Chase & Co. reduced their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday. Truist Financial lowered their price objective on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Mizuho decreased their price target on IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research report on Thursday, May 15th. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Finally, HSBC cut IQVIA from a "buy" rating to a "hold" rating and decreased their target price for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $228.14.

IQVIA Stock Performance

IQV traded down $7.61 on Wednesday, reaching $137.34. 2,870,722 shares of the stock were exchanged, compared to its average volume of 1,543,602. The company's 50-day moving average price is $157.30 and its 200 day moving average price is $184.65. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $23.76 billion, a PE ratio of 18.31, a PEG ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. IQVIA's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.54 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.